VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
VaxCT
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Pfs230D1-EPA/ AS01
Vaccine Information
  • Vaccine Name: Pfs230D1-EPA/ AS01
  • Target Pathogen: Plasmodium spp.
  • Target Disease: Malaria
  • Type: Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Antigen: Pfs230 domain 1: Pre-fertilization antigens, expressed during gametocyte development in human (Duffy et al. 2021)
  • Adjuvant: EPA: a recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa (Talaat et al., 2016); AS01: AS01: a liposomal preparation that incorporates the Toll-like receptor 4 (TLR4) ligand 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and the saponin fraction Quillaja saponaria 21 (QS-21) (Rausch et al., 2023)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: The Pfs230D1-EPA/AS01 uses the Pfs230D1 pre-fertilization antigen conjugated with EPA nanoparticles with GSK platform AS01 as the vaccine adjuvant tested on mice.
Host Response

Mouse Response

  • Host Strain: CD-1 Mice
  • Immune Response: Pfs230D1-EPA induces higher titers and IgG levels in AS01 vs. alum adjuvants in mice (Rausch et al., 2023)
References
Duffy et al. 2021: Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali [https://clinicaltrials.gov/ct2/show/NCT05135273?term=vaccine&cond=Malaria%2CFalciparum&draw=2&rank=2]
Rausch et al., 2023: Rausch KM, Barnafo EK, Lambert LE, Muratova O, Gorres JP, Anderson C, Narum DL, Wu Y, Morrison RD, Zaidi I, Duffy PE. Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. iScience. 2023; 26(7); 107192. [PubMed: 37485364].
Talaat et al., 2016: Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. PloS one. 2016; 11(10); e0163144. [PubMed: 27749907].